Navigation Links
Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
Date:1/27/2008

d LV with oxaliplatin) after three months of therapy or sooner if significant (Grade 3 or greater) neurotoxicity develops. For more information, please see http://www.nccn.org.

In the Phase 1 study, 50 patients were treated with picoplatin on either an every-two-week or an every-four-week basis in combination with the standard of care every-two-week dose of 5FU and LV. Patients received up to 28 cycles, and the therapy was well tolerated. Increased hematological toxicity was observed at higher doses. None of the patients treated with picoplatin exhibited a Grade 3 or higher neuropathy and only 9 of 45 patients (20 percent) experienced mild neuropathy. No neuropathy of Grade 2 or greater was observed in the 26 patients who received greater than or equal to 400 mg/m squared picoplatin. Mild nephro- and oto- toxicity were observed infrequently. The dose limiting toxicity (DLT) was most frequently hematological with neutropenia and thrombocytopenia. The maximum tolerated dose was established in the every-four-week schedule at 150 mg/m squared. The maximum tolerated dose for the every-two-week schedule has not yet been reached.

Based on the evidence of a more attractive safety profile of picoplatin in this combination (FOLPI) compared to the standard of care regimen with oxaliplatin (FOLFOX) as well as clinical activity in the Phase 1 study, the Company initiated a randomized Phase 2 trial in November, 2007 to evaluate intravenous picoplatin in the first-line treatment of mCRC. The Phase 2 trial is intended to generate proof-of-concept data to further evaluate efficacy and safety, including neuropathy of picoplatin in combination with 5-FU and LV (FOLPI versus FOLFOX) and to provide support for a potential registrational Phase 3 trial. The Company expects to present data from the Phase 1 and 2 mCRC program in scientific forums around mid year.

About Picoplatin

Picoplatin is an intravenous chemoth
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
5. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
9. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... Stanley Global Healthcare Conference on Wednesday, September 10. ... Executive Officer, will provide an update on the company, ... Pacific Daylight Time).   A webcast of ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... REDWOOD CITY, Calif., July 19, 2011 Cardica, ... that Andreas Kuthe, M.D., Chief of General Surgery ... successfully completed a total of five laparoscopic procedures ... cutting and stapling device. These included several sigmoidectomies, ...
... Agility Health, a leading national provider ... patients, healthcare providers and employers, today announced the ... clinics.  Agility Health,s newest facility, located in Plainwell, ... to 23 owned or partnered facilities and follows ...
Cached Medicine Technology:Dr. Andreas Kuthe Performs First Laparoscopic Procedures Using Cardica's Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device 2Dr. Andreas Kuthe Performs First Laparoscopic Procedures Using Cardica's Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device 3Agility Health Expands National Outpatient Clinic Group with New Michigan Facility 2
(Date:8/29/2014)... 2014 Healthpointe is pleased to ... Therapy students via Clinical Rotations. Physical ... shadowing Healthpointe providers and specialists throughout their daily ... clinical experience and learn professional preparation. ... insight into several patient care techniques and expand ...
(Date:8/29/2014)... 2014 Healthpointe is pleased to announce ... their practice. Dr. Chuang garners extensive experience in the ... arthroscopic and reconstructive treatments of the knees, hips, and ... general and sports-related orthopedic needs. , Dr. ... As an Orange County native, he graduated with two ...
(Date:8/29/2014)... Healthpointe Medical Group, one of Southern California’s ... LAXMed. The medical center is less than 2 miles from ... the 405 freeway. , The LAX clinic marks the ... is located at: 8610 S. Sepulveda Blvd., Suite 204 Los ... LAX office will provide the same comprehensive services as Healthpointe’s ...
(Date:8/29/2014)... released yesterday by the Mental Health Commission of ... training and education that police personnel receive. , ... for Canada,s police community, and today,s report builds ... and people with mental illnesses," says Queen,s adjunct ... interest in the area of police psychology. "This ...
(Date:8/29/2014)... 29, 2014 A team of experts ... is on its way to the 2014 National Safety ... Convention Center to exhibit and demonstrate a suite of ... industrial environments. Etymotic’s safety earphones and high-definition earplugs are ... at the show. , The company’s HD5 high-definition, ...
Breaking Medicine News(10 mins):Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Healthpointe is Honored to Induct Orthopedic Surgeon into Their Team 2Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2Health News:Report advocates improved police training 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2
... Clinical and Technology Enhancements to Care Management ... ... 6 The American Board of Quality,Assurance and Utilization Review Physicians, ... which will,examine the latest developments in managing individuals with chronic or,high-cost ...
... company, is announcing an, upcoming stand-up comedy show to ... May 6 KXBEVENTS is presenting the inaugural,"Laugh San ... Lymphoma,Society to fund blood cancer research, education and patient ... from 8:00 p.m. to 10:00 p.m. at,4th & B ...
... Offers New Payment Options (10-Pay, 15-Pay or 20-Pay), - Offers Long Term Care Rider(1) ... ... - Easy ... a,new, highly competitive Protection Whole Life(2) policy that combines,affordable, guaranteed death benefit protection, guaranteed ...
... predictors of organ failure, study says , , TUESDAY, May ... heart tissue that in turn boosts heart failure risk, ... , The latest findings from the Multiethnic Study ... large scale of evidence of such a link and ...
... (May 6, 2008) More and more U.S. college students ... its becoming a growing public health issue, according to a ... The findings offer important insight into the prevalence and perceptions ... May issue of the Journal of Adolescent Health. The article ...
... MTD ) today announced the webcast of its,presentation ... Vegas on,Tuesday, May 13, 2008, at 8:40 a.m. Pacific ... of the presentation, visit the investor relations,page on the ... replay of the,webcast will be available for seven days., ...
Cached Medicine News:Health News:ABQAURP Hosts Third Annual Medical Management Conference in Orlando 2Health News:KXBEVENTS Presents 'Laugh San Diego 2008' Stand-Up Comedy Show to Benefit the Leukemia & Lymphoma Society 2Health News:John Hancock Launches New Fully Guaranteed Whole Life Insurance Product 2Health News:John Hancock Launches New Fully Guaranteed Whole Life Insurance Product 3Health News:Obesity-Related Inflammation Boosts Heart Risks 2Health News:Waterpipe smoking on college campuses may contribute to growing public health problem 2
Anterior Chamber Needle, 21 g., 8 mm from bend to tip. Overall length 25 mm. 5/box....
Anterior Chamber Needle, 25 g. Angled. 9 mm angled tip. Overall length 19 mm. 5/box....
Anterior Chamber Needle, 20 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with left hook. 10 mm angled shaft with 2.5 mm left hook tip. Overall length 20 mm. 5/box....
Medicine Products: